216 related articles for article (PubMed ID: 20385104)
1. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
Chapman JV; Gouazé-Andersson V; Messner MC; Flowers M; Karimi R; Kester M; Barth BM; Liu X; Liu YY; Giuliano AE; Cabot MC
Biochem Pharmacol; 2010 Aug; 80(3):308-15. PubMed ID: 20385104
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
3. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity.
Chapman JV; Gouazé-Andersson V; Cabot MC
Int J Oncol; 2010 Dec; 37(6):1591-7. PubMed ID: 21042729
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.
Morad SA; Madigan JP; Levin JC; Abdelmageed N; Karimi R; Rosenberg DW; Kester M; Shanmugavelandy SS; Cabot MC
Biochem Pharmacol; 2013 Apr; 85(8):1057-65. PubMed ID: 23353700
[TBL] [Abstract][Full Text] [Related]
5. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.
Morad SA; Ryan TE; Neufer PD; Zeczycki TN; Davis TS; MacDougall MR; Fox TE; Tan SF; Feith DJ; Loughran TP; Kester M; Claxton DF; Barth BM; Deering TG; Cabot MC
J Lipid Res; 2016 Jul; 57(7):1231-42. PubMed ID: 27140664
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
Chapman JV; Gouazé-Andersson V; Karimi R; Messner MC; Cabot MC
Exp Cell Res; 2011 Jul; 317(12):1736-45. PubMed ID: 21396934
[TBL] [Abstract][Full Text] [Related]
7. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen.
Furlong SJ; Mader JS; Hoskin DW
Oncol Rep; 2006 May; 15(5):1385-90. PubMed ID: 16596215
[TBL] [Abstract][Full Text] [Related]
8. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
9. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
[TBL] [Abstract][Full Text] [Related]
10. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.
Morad SA; Levin JC; Shanmugavelandy SS; Kester M; Fabrias G; Bedia C; Cabot MC
Mol Cancer Ther; 2012 Nov; 11(11):2352-61. PubMed ID: 22962326
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of short-chain ceramide and dihydroceramide analogues in Chinese hamster ovary (CHO) cells.
Ridgway ND; Merriam DL
Biochim Biophys Acta; 1995 Apr; 1256(1):57-70. PubMed ID: 7742357
[TBL] [Abstract][Full Text] [Related]
12. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics.
Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
Int J Oncol; 1999 Sep; 15(3):541-6. PubMed ID: 10427137
[TBL] [Abstract][Full Text] [Related]
13. Short-chain C6 ceramide sensitizes AT406-induced anti-pancreatic cancer cell activity.
Zhao X; Sun B; Zhang J; Zhang R; Zhang Q
Biochem Biophys Res Commun; 2016 Oct; 479(2):166-172. PubMed ID: 27562715
[TBL] [Abstract][Full Text] [Related]
14. Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells.
Morad SA; Bridges LC; Almeida Larrea AD; Mayen AL; MacDougall MR; Davis TS; Kester M; Cabot MC
Cancer Lett; 2016 Jul; 376(2):199-204. PubMed ID: 27045476
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.
Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
[TBL] [Abstract][Full Text] [Related]
17. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.
Furlong SJ; Ridgway ND; Hoskin DW
Int J Oncol; 2008 Mar; 32(3):537-44. PubMed ID: 18292930
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
Morad SA; Cabot MC
Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
[TBL] [Abstract][Full Text] [Related]
19. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
20. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells.
Wang H; Charles AG; Frankel AJ; Cabot MC
Urology; 2003 May; 61(5):1047-52. PubMed ID: 12736045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
